Please use this identifier to cite or link to this item:
Title: Surfactant protein D multimerization and gene polymorphism in COPD and asthma
Authors: Fakih, Dalia
Akiki, Zeina
Junker, Kirsten
Medlej-Hashim, Myrna
Waked, Mirna
Salameh, Pascale
Holmskov, Uffe
Bouharoun-Tayoun, Hasnaa
Chamat, Soulaima
Sorensen, Grith L
Jounblat, Rania
Affiliations: Faculty of Medicine 
Keywords: Asthma
Chronic obstructive pulmonary disease
Single nucleotide polymorphism
Surfactant protein D
Issue Date: 2018
Publisher: Wiley Online Library
Part of: Respirology
Volume: 23
Issue: 3
Start page: 298
End page: 305
Background and objective
A structural single nucleotide polymorphism rs721917 in the surfactant protein D (SP-D) gene, known as Met11Thr, was reported to influence the circulating levels and degree of multimerization of SP-D and was associated with both COPD and atopy in asthma. Moreover, disease-related processes are known to degrade multimerized SP-D, however, the degree of the protein degradation in these diseases is not clarified. We aimed to determine the distribution of multimerized (high molecular weight (HMW)) and non-multimerized (low molecular weight (LMW)) species of serum SP-D and their correlation with genetic polymorphisms and presence of disease in Lebanese COPD and asthmatic patients.

Serum SP-D levels were measured by ELISA in 88 COPD, 121 asthmatic patients and 223 controls. Randomly selected subjects were chosen for genotyping of rs721917 and multimerization studies. HMW and LMW SP-D were separated by gel permeation chromatography.

Serum SP-D levels were significantly increased in patients with COPD, but not in asthmatic patients, when compared to controls. Met11Thr variation strongly affected serum SP-D levels and the degree of multimerization, but was not associated with COPD and asthma in the study. Remarkably, HMW/LMW serum SP-D ratio was significantly lower in Met11/Met11 COPD and asthmatic patients compared to controls.

Collectively, non-multimerized species of serum SP-D were dominant in COPD and asthmatic patients suggesting that degradation of SP-D takes place to a significant degree in pulmonary disease. Assays that can separate SP-D proteolytic breakdown products or modified forms from naturally occurring SP-D trimers may result in optimal disease markers for pulmonary inflammatory diseases.
ISSN: 13237799
DOI: 10.1111/resp.13193
Ezproxy URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Aug 13, 2022

Record view(s)

checked on Aug 14, 2022

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.